Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
Purpose To analyze the prognostic impact of mutated KIT (mut KIT) in core-binding factor
acute myeloid leukemia (AML) with inv (16)(p13q22) and t (8; 21)(q22; q22). Patients and …
acute myeloid leukemia (AML) with inv (16)(p13q22) and t (8; 21)(q22; q22). Patients and …
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
A Hochhaus, S Kreil, AS Corbin, P La Rosee… - Leukemia, 2002 - nature.com
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a
promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML) …
promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML) …
[HTML][HTML] Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …
Cytogenetic and molecular mechanisms of resistance to imatinib
A Hochhaus - Seminars in hematology, 2003 - Elsevier
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (Gleevec)(formerly STI571)
is a promising new therapeutic strategy in patients with chronic myelogenous leukemia …
is a promising new therapeutic strategy in patients with chronic myelogenous leukemia …
[HTML][HTML] ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
L Schönfeld, J Rinke, A Hinze, SN Nagel, V Schäfer… - Leukemia, 2022 - nature.com
Gene mutations independent of BCR:: ABL1 have been identified in newly diagnosed
patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in …
patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in …
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
M Schmidt, J Rinke, V Schäfer, S Schnittger… - Leukemia, 2014 - nature.com
To study clonal evolution in chronic myeloid leukemia (CML), we searched for BCR-ABL-
independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph …
independent gene mutations in both Philadelphia chromosome (Ph)-negative and Ph …
[HTML][HTML] Lack of clinical efficacy of imatinib in metastatic melanoma
S Ugurel, R Hildenbrand, A Zimpfer, P La Rosee… - British journal of …, 2005 - nature.com
This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised
melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit …
melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit …
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
M Emig, S Saussele, H Wittor, A Weisser, A Reiter… - Leukemia, 1999 - nature.com
We sought to establish a rapid and reliable RT-PCR approach for detection and
quantification of BCR-ABL fusion transcripts using the LightCycler technology. This device …
quantification of BCR-ABL fusion transcripts using the LightCycler technology. This device …
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are …
A Hochhaus, A Reiter, SSA Reichert… - Blood, The Journal …, 2000 - ashpublications.org
A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a
complete response (CR) to treatment with interferon-(IFN), defined as the disappearance …
complete response (CR) to treatment with interferon-(IFN), defined as the disappearance …